Figure 1

Association between PDZK1 upregulation and breast malignancy. (A) The extent of PDZK1 immunoreactivity was expressed as a percentage of total tissues. Medium and high signals were combined and compared with percentage of cores with low or negative signals. *Difference from the number of PDZK1-negative cancerous tissues; p ≤ 0.005. (B) Represents scanned TMA sections (mostly cancer, left panel, or mostly normal, right panel, tissues) subjected to immunohistochemical staining with antibodies to human PDZK1. (C) Tissue cores representing normal breast and cancer tissue. Note the mostly cytoplasmic distribution and the occasional nuclear or perinuclear localization of PDZK1. Bar: 4 µm. Nuc, Nuclear staining; Peri-Nuc, perinuclear staining. (D) Histoscores of PDZK1 immunoreactivity according to age of women from which tumors were collected. *Difference from the number of PDZK1-positive cancerous tissues collected from women younger than 40 years of age; p ≤ 0.005. ^#Difference from the number of PDZK1-positive tissues from women between 46–55 years of age; p ≤ 0.005.